로딩 중…
지수 로딩 중…
Green Cross Medical Science Corporation
142280· KOSDAQ· Health Care· Health Care Equipment & Services
₩3,070-0.49%
2026-11-02
Financials
Valuation Metrics
Green Cross Medical Science Corporation's Market Cap is ₩732B. At end of 2025 it was ₩960B. Ranked #1396 of 2,410 in KR market (top 58%), #785 of 1,631 on KOSDAQ (top 48%), #51 of 94 in Health Care Equipment & Services (top 54%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 73.21B KRW | KR#1,396/2,410 Sec#51/94 |
| Revenue | 102.16B KRW | KR#1,404/2,410 Sec#35/94 |
| Net Income | -2.03B KRW | KR—/2,410 Sec—/94 |
| Total Assets | 90.51B KRW | KR#1,856/2,410 Sec#56/94 |
| Net Assets | 46.37B KRW | KR#1,954/2,410 Sec#62/94 |
| Employees | 133 | KR#1,411/2,410 Sec#47/94 |
| Value | ||
| P/B | 1.59x | KR#1,869/2,410 Sec#62/94 |
| P/S | 0.72x | KR#1,240/2,410 Sec#18/94 |
| EV/EBITDA | 35.22x | KR#1,279/2,410 Sec#42/94 |
| FCF Yield | 3.38% | KR#980/2,410 Sec#30/94 |
| Profitability | ||
| ROE | -4.38% | KR#1,774/2,410 Sec#60/94 |
| ROA | -2.24% | KR#1,770/2,410 Sec#59/94 |
| Op. Margin | 2.32% | KR#1,338/2,410 Sec#48/94 |
| Revenue Growth | -8.46% | KR#1,882/2,410 Sec#80/94 |
| Earnings Growth | -168.46% | KR#1,220/2,410 Sec#43/94 |
| Financial Health | ||
| Debt Ratio | 95.21% | KR#1,506/2,410 Sec#76/94 |
| Total Debt | 10.58B KRW | KR#1,599/2,410 Sec#49/94 |
| FCF | 2.48B KRW | KR#1,050/2,410 Sec#30/94 |
| Cash | 372.6M KRW | KR#2,362/2,410 Sec#94/94 |
| Current Ratio | 1.47x | KR#1,227/2,410 Sec#66/94 |
| Net Debt/EBITDA | 4.31x | KR#988/2,410 Sec#38/94 |
| Dividend | ||
| Div. Growth | 0.00% | KR—/2,410 Sec—/94 |
| Performance | ||
| 1Y Return | -23.63% | KR#1,203/2,410 Sec#36/94 |
| 1M Return | -7.67% | KR#631/2,410 Sec#24/94 |
| From 52W High | -53.90% | KR#1,290/2,410 Sec#48/94 |
| 1Y MDD | -61.56% | KR#1,529/2,410 Sec#50/94 |
| Trading | ||
| Volume | 270,029 shares | KR#200/2,410 Sec#4/94 |
| Trading Value | 827.8M KRW | KR#551/2,410 Sec#13/94 |
| Foreign Own. | 1.02% | KR#2,023/2,410 Sec#77/94 |
| Per Share | ||
| EPS | -85 KRW | KR—/2,410 Sec—/94 |
| BPS | 1,935 KRW | KR#2,092/2,410 Sec#71/94 |
Company Info
동사는 2003년 체외진단용의약품 제조판매를 목적으로 설립되었고, 2015년 녹십자메디스를 인수하며 자회사로 편입하였음. 2019년 충북 음성에 국내 최대 혈액투석액 생산시설을 갖추었고, 다양한 진단시약 및 의료기기, 혈액투석액 사업을 영위하고 있음. 유전체분석과 AI를 활용한 다중 진단 플랫폼으로의 전환과 첨단 POCT 진단시스템 개발을 바탕으로 혁신을 추구하고 있음. 녹십자엠에스는 2003년에 설립되었으며 경기도 용인시에 본사를 두고 있습니다.